C12N 2770/10011
Arteriviridae
C12N2770/10011 (Arteriviridae) appears on 259 US grants and 316 published applications in this corpus.
Search patents in C12N- Granted patents
- 259
- Published applications
- 316
- Assignees
- 146
- Inventors
- 532
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 2 | 0 |
| 1999 | 9 | 0 |
| 2000 | 6 | 0 |
| 2001 | 6 | 2 |
| 2002 | 8 | 4 |
| 2003 | 5 | 19 |
| 2004 | 2 | 11 |
| 2005 | 3 | 8 |
| 2006 | 6 | 12 |
| 2007 | 8 | 7 |
| 2008 | 5 | 13 |
| 2009 | 10 | 19 |
| 2010 | 10 | 18 |
| 2011 | 8 | 16 |
| 2012 | 11 | 16 |
| 2013 | 10 | 16 |
| 2014 | 14 | 21 |
| 2015 | 15 | 15 |
| 2016 | 7 | 16 |
| 2017 | 15 | 18 |
| 2018 | 19 | 16 |
| 2019 | 13 | 11 |
| 2020 | 16 | 16 |
| 2021 | 10 | 5 |
| 2022 | 8 | 8 |
| 2023 | 5 | 11 |
| 2024 | 6 | 8 |
| 2025 | 8 | 5 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/10034Use of virus or viral component as vaccineIndexing code203
- C12N 2770/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code111
- C12N 2770/10021Viruses as suchIndexing code73
- C12N 2770/10061Methods of inactivation or attenuationIndexing code61
- C12N 2770/10051Methods of production or purification of viral materialIndexing code33
- C12N 2770/10041Use of virus, viral particle or viral elements as a vectorIndexing code25
- C12N 2770/10071Demonstrated in vivo effectIndexing code18
- C12N 2770/10023Virus like particles [vlp]Indexing code6
All 12 subgroupsShow fewer
Recent patents
- M Hyo multivalent vaccine and uses thereof16 Jun 2026US 12,653,876 B2
- N protein epitope mutation marker for preparing epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof19 May 2026US 12,629,411 B2Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
- Combination of vaccines to prophylactically treat a pig7 Apr 2026US 12,594,328 B2Intervet Inc.
- Vaccine to protect against mycoplasma hyopneumoniae3 Mar 2026US 12,564,629 B2Vaxinano SAS
- Recombinant arterivirus replicon systems and uses thereof4 Nov 2025US 12,460,229 B2Janssen Pharmaceuticals, Inc.
- Methods and compositions for vaccinating piglets against prrs-1 virus9 Jul 2026US 2026/0191945 A1Zoetis Services LLC
- Porcine interferon-like recombinant protein and use thereof9 Jul 2026US 2026/0191946 A1Bodn Biotech Inc.
- Vaccine to protect against mycoplasma hyopneumoniae28 May 2026US 2026/0144863 A1Vaxinano SAS
- Nadc34-like prrsv-2 vaccine candidate strain and application thereof2 Apr 2026US 2026/0091100 A1Yangzhou University
- Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof12 Mar 2026US 2026/0069672 A1Boehringer Ingelheim Vetmedica GmbH
Most cited
By later US patents
- European vaccine strains of the porcine reproductive and respiratory syndrome virus110US 5,925,359 AAkzo Nobel N. V. · 1999
- Low pathogencity PRRS live virus vaccines and methods of preparation thereof81US 5,690,940 ARegents of the University of Minnesota · 1997
- Method of growing and attenuating a viral agent associated with mystery swine disease76US 5,476,778 ABoehringer Ingelheim Animal Health, Inc. · 1995
- PRRS vaccines74US 7,368,117 B2Boehringer Ingelheim Vetmedica GmbH · 2008
- Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome71US 5,695,766 AIowa State University Research Foundation, Inc. · 1997